Symposium 8 Novel therapeutic strategy for AML

[SY8-1] The latest (and greatest?) FLT3 inhibitor

Mark Levis (Hematologic Malignancies/Oncology, Johns Hopkins University, United States of America)

Dr. Mark Levis completed a baccalaureate in genetics at U.C. Berkeley, and is a graduate of the Medical Scientist Training Program from U.C. San Francisco. He completed his residency training in internal medicine and a fellowship in medical oncology at Johns Hopkins University. He is a Professor of Oncology and the Director of the Adult Leukemia Service and Co-Director of the Division of Hematologic Malignancies at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. His broad research goals are to identify and validate novel molecular therapeutic targets in hematopoietic malignancies. His research group is interested in the identification and pre-clinical development of novel targeted therapies, and, in particular, the translational step of this research by using correlative studies to incorporate these novel therapies into existing treatments. Currently, Dr. Levis is actively involved in the pre-clinical and clinical development of small molecule kinase inhibitors targeting signaling pathway in acute myeloid leukemia, with a particular focus on FLT3.